N/A
N=150
Developing E-liquid Product Standards (Sweet Spot Study)
Nicotine · Nicotine Vaping · E-cigarette Use
Bottom Line
View on ClinicalTrials.gov: NCT05864586 ↗Enrolled (actual)
150
Serious AEs
0.0%
Results posted
Apr 2025
Primary outcome: Primary: Behavioral Intentions for Continued Use — 3.73; 3.88; 3.91; 3.74 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Vaping study EC A (Behavioral); Vaping study EC B (Behavioral); Vaping study EC C (Behavioral); Vaping study EC D (Behavioral); Vaping study EC E (Behavioral); Vaping study EC F (Behavioral); Vaping study EC G (Behavioral); Vaping study EC H (Behavioral); Vaping study EC I (Behavioral); Vaping study EC J (Behavioral)
- Age
- Adult · 21+ yrs
- Sex
- All
- Sponsor
- Ohio State University Comprehensive Cancer Center
- Primary completion
- Feb 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Behavioral Intentions for Continued Use |
3.73; 3.88; 3.91; 3.74; 3.55; 3.74 | — |
| PRIMARY Intensity of Sensory Attributes |
13.05; 13.03; 16.17; 17.53; 21.29; 19.39 | — |
| PRIMARY Degree of Liking or Disliking of Sensations |
8.34; 5.33; 11.83; 5.42; 0.05; 6.89 | — |
| SECONDARY Subjective Appeal |
3.19; 3.21; 3.20; 3.09; 2.88; 3.13 | — |
Summary
The Sweet Spot Study aims to evaluate the effect of e-liquids with nicotine varying in freebase (FB) levels and concentrations on the appeal of electronic cigarettes (ECs) in young adult EC users with minimal/no history of smoking and older adult smokers.
Eligibility Criteria
Inclusion criteria
- Young adult e-cigarette user or older adult smoker
- Willing to abstain from all nicotine product use for 12 hours prior to the study visit
- Read and speak English
Exclusion criteria
- Currently attempting to quit nicotine products
- Currently pregnant, planning to become pregnant, or breastfeeding
- Current or past use of tobacco products other than e-cigarettes or cigarettes
- Self-reported diagnosis of lung disease
- Self-reported new or unstable cardiovascular disease
Data sourced from ClinicalTrials.gov (NCT05864586). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.